

31 March 2026

Urothelial Cancer Treatment

Question One

Do you treat patients for urothelial cancer within your trust? (Yes/No) If No, to which trust(s) do you typically refer patients for treatment? Yes

Question Two

How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Atezolizumab (Tecentriq)	<5
Avelumab (Bavencio)	0
Carboplatin single agent or in any other combination	<5
Carboplatin with Gemcitabine	<5
Carboplatin with Gemcitabine + Avelumab (Bavencio)	0
Carboplatin with Paclitaxel	0
Cisplatin single agent or in any other combination	0
Cisplatin with Gemcitabine	<5
Cisplatin with Gemcitabine + Nivolumab (Opdivo)	0
Cisplatin with Gemcitabine + Avelumab (Bavencio)	0
Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev)	<5
Nivolumab (Opdivo)	0
Pembrolizumab (Keytruda)	0
Other active systemic anti-cancer therapy **	Paclitaxel <5
Palliative care only **	
Erdafitinib	0
Cisplatin + Gemcitabine + Durvalumab (Imfinzi)	0
BCG therapy	0
Chemo-Radiation Therapy**	

** The number of patients treated with Radiotherapy for the last 3 months, with C67 as a diagnosis code was 24. 16 of these were palliative and the 8 were radical.

We are unable to confirm if these patients were chemo-radiotherapy or radiotherapy only. We estimate that compliance with this (element of the) request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

We have presented the figure as less than 5 (<5) to prevent the potential identification of individuals. This information is withheld under Section 40(2) of the Freedom of Information Act 2000, as releasing specific low numbers could disclose personal data.